Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kansai Medico Issues Apology over Harvoni Counterfeits
January 24, 2017
- Ferring Speeding Up R&D in Core Sectors, Positive on Licensing and M&A: Japan CEO
January 23, 2017
- Stivarga Gets Priority Review for 2nd-Line Liver Cancer Treatment
January 23, 2017
- Debiopharm’s Appeal on Elplat Patent Suit Dismissed: Towa
January 23, 2017
- BMS-Ono Pair, Merck Settle Keytruda Patent Suits
January 23, 2017
- Opdivo Extends OS in Advanced Gastric Cancer: Ono
January 23, 2017
- Takeda Taps NY Biotech to Develop Its Pediatric Epilepsy Med
January 20, 2017
- Daiichi Sankyo’s 2nd ADC Now in Japan PI/II for HER3-Positive Breast Cancer
January 20, 2017
- Hiroshi Kasamoto Named as Bioverativ Japan President
January 20, 2017
- JCR to Initiate PI/II Study in March of Therapeutic Enzyme for Hunter Syndrome that Applies Blood-Brain Barrier Technology
January 20, 2017
- Ethical Drug Sales Down 3.6% in November: Crecon Report
January 19, 2017
- Gilead Japan to Switch Sovaldi, Harvoni Bottles to Blister Packs
January 19, 2017
- Nichi-Iko, Meiji Seika Pharma Obtain New Indications for Zosyn Generics
January 19, 2017
- Gilead Asks Pharmacists to Open Harvoni Bottles in Front of Patients after Fake Drug Found
January 18, 2017
- Mitsubishi Tanabe to Shake Up Organization in April
January 17, 2017
- Eisai to Take Over Rights to Roche/Chugai’s Insomnia Drug
January 17, 2017
- FDA Orphan Status Granted to Nippon Shinyaku’s DMD Med
January 17, 2017
- Dasotraline Meets Primary Endpoint in PII/III Study in Adult Patients with Binge Eating Disorder: Sumitomo Dainippon
January 17, 2017
- Hisamitsu Suffers Double-Digit Plunge in March-November Sales
January 16, 2017
- Shionogi’s Novel Antibacterial Shows Effectiveness in Urinary Tract Infection
January 13, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…